文献速递系统性红斑狼疮类风湿关节炎

系统性红斑狼疮中利妥昔单抗对外周血和肾脏B细胞清除的差异:奥妥珠单抗的机会?

Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

本研究分析SLE患者利妥昔单抗治疗后外周血和肾脏B细胞清除情况,并与RA患者比较。SLE患者B细胞清除持续时间较RA短,利妥昔单抗治疗后肾活检仍可检测到B细胞且与不良反应相关。体外全血实验显示奥妥珠单抗诱导B细胞清除优于利妥昔单抗,且不受BAFF过量影响。

要点

  • SLE患者利妥昔单抗介导的B细胞清除持续时间较RA患者短。
  • 利妥昔单抗治疗后肾活检仍可检测到B细胞,且与不良反应相关。
  • 体外实验中奥妥珠单抗诱导B细胞清除优于利妥昔单抗,不受BAFF过量影响。

核心结论

  • SLE中利妥昔单抗介导的B细胞清除效率低于RA。
  • 利妥昔单抗治疗后肾脏B细胞存在与不良结局相关。
  • 未发现所测B细胞相关、临床或实验室参数与利妥昔单抗B细胞清除效率之间存在显著关系。
  • 奥妥珠单抗在诱导B细胞清除方面优于利妥昔单抗。

研究设计与样本

  • 分析SLE患者(n=71)利妥昔单抗治疗前及治疗后1、2、3、6个月CD19+ B细胞计数,并与RA患者(n=27)比较。
  • 分析利妥昔单抗治疗后肾活检样本(n=6)中B细胞的存在。
  • 分析B细胞清除持续时间与患者人口学特征及B细胞CD20和FcγRIIb表达的关系。
  • 体外全血实验分析B细胞激活因子(BAFF)对利妥昔单抗和奥妥珠单抗诱导B细胞清除效率的影响。

主要发现

  • SLE患者(n=71)B细胞清除持续时间较RA患者(n=27)短。
  • 利妥昔单抗治疗后肾活检样本(n=6)中所有反应不佳的患者均可检测到B细胞,而同一患者外周血B细胞仍低或不可检测。
  • 外周血B细胞清除与患者年龄、疾病病程、血清C3水平或B细胞表面蛋白CD20和FcγRIIb表达水平之间无显著关系。
  • 体外全血实验中,无论BAFF是否过量,奥妥珠单抗诱导B细胞清除均优于利妥昔单抗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate key factors that may contribute to the variability of rituximab-mediated peripheral and renal B cell depletion (BCD) in SLE. METHODS: We analysed: (i) CD19+ B cell counts in patients with SLE before and 1, 2, 3 and 6 months after treatment with rituximab, comparing them with RA patients; (ii) the presence of B cells in renal biopsies after rituximab therapy; (iii) whether the duration of BCD correlated with patient demographics and B cell expression of CD20 and FcγRIIb; and (iv) the effect of B cell activation factor (BAFF) on the efficiency of rituximab and obinutuzumab at inducing BCD in whole blood assays, in vitro. RESULTS: In SLE (n = 71), the duration of BCD was shorter compared with RA (n = 27). B cells were detectable in renal biopsy samples (n = 6) after treatment with rituximab in all patients with poor response while peripheral blood B cells remained low or undetectable in the same patients. There were no significant relationships between peripheral BCD and patient age, disease duration, serum C3 levels or the level of expression of B cell surface proteins CD20 and FcγRIIb. Obinutuzumab was more efficient than rituximab at inducing BCD in whole blood assays, regardless of excess BAFF. CONCLUSIONS: BCD in SLE is less efficient than in RA. Renal B cell presence following rituximab treatment was associated with poor outcomes. No significant relationships between any measured B cell related, clinical or laboratory parameters and the efficiency of BCD by rituximab was found. Obinutuzumab was superior to rituximab at inducing BCD.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Reddy VR, Pepper RJ, Shah K, et al. Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab? Rheumatology (Oxford). 2022. PMID: 34788412. doi:10.1093/rheumatology/keab827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。